Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

BOULDER, Colo. and MONTREAL, Jan. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the enrollment of the first patient in a Phase 2 clinical trial (Trial CL002) evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Vidaza(R) (azacitidine for injection), Pharmion's DNA demethylating agent, in patients with relapsed or refractory Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL).

Patients will receive 75 mg/m2 of Vidaza either intravenously or subcutaneously in combination with an oral dose of MGCD0103 in 28 day cycles. Key objectives for this study are to determine the overall response rate, progression free survival and duration of response. The trial will enroll up to 75 patients at cancer centers in North America and will include a pharmacokinetic equivalency study.

"We are aggressively exploring the utility of epigenetic drug combinations in the treatment of cancer," said Andrew Allen, Pharmion's executive vice president and chief medical officer. "The biology of cancer suggests multiple epigenetic mechanisms cooperate to silence tumor suppressor genes, which raises the simple hypothesis that attacking these mechanisms with drug combinations may be superior to single-agent therapy. In this trial, we are combining Vidaza, our DNA methyltransferase inhibitor, with MGCD0103, our isotype-selective HDAC inhibitor, in a clinical study of this therapeutic approach. We are unique in our ability to conduct a trial like this, using drugs from our own portfolio."

"We are delighted to be participating in this trial of Vidaza and MGCD0103," commented Dr. Anas Younes, Professor of Medicine
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at June 30, ... March 31, 2014."The second half of 2014 will be an ... milestones for a number of our late-stage clinical programs," said ... "The first of these is the potential US and EU ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources ... brought about by the Affordable Care Act ... prescribing of pharmaceutical therapies. The ACA altered ... through new regulations and expanded access via ... the health exchanges—state-based marketplaces set up by ...
(Date:7/31/2014)... Hovione today announced that its API ... passed a pre-approval inspection by the US Food and Drug ... FDA Consumer Safety Officer, Ms. Britanny Terhar , lasted ... July and concluded on the 25 th . The inspection ... guidelines of Good Manufacturing Practices (GMP) and no Form 483 ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
(Date:8/1/2014)... 1, 2014 (BRONX, NY) Scientists at ... have found that bacteria that aid in digestion help ... in the journal Immunity , could yield new ... range of other disorders. , The research involved the ... role of these microorganisms in promoting or preventing disease ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Women who serve ... alcohol than their civilian peers, a new study suggests. ... to consume alcohol. However, these researchers found that women ... men. This may be due to concerns about sexual ... use is tightly linked to sexual assault, both within ...
(Date:8/1/2014)... European gas chromatography systems report defines and segments the concerned ... gas chromatography systems market in Europe is valued at $191.1 ... $247.6 million by 2018, at a CAGR of 5.3% from ... European gas chromatography systems market, to get an idea of ... the segmentation of gas chromatography systems market in the same ...
(Date:8/1/2014)... The North America Sports Drink Market report ... with analysis and forecast of revenue. The Sports Drink Market ... million in 2012 to $6,243 million by 2018, at a ... the TOC of the North America Sports Drink market report, ... also provides a glimpse of the segmentation in the North ...
(Date:8/1/2014)... Society of America (GSA) the nation,s largest ... has chosen Carole B. Lewis, PT, DPT, PhD, GTC, ... the Excellence in Rehabilitation of Aging Persons Award. , ... contributions in the field of rehabilitation. The awardee,s work ... care, or publications that may include scholarly works, books, ...
Breaking Medicine News(10 mins):Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:Women in Military Drink Less Than Civilians, Report Shows 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2
... blood pressure is well known, however// a new study reports ... published today in the Open Access journal Environmental Health for ... of salt particles can have just the same effect on ... an occupational health hazard for workers in salt factory. It ...
... Authority (NPPA) has been working// on bringing down the ... the manufacturers and has finally succeeded. According to NPPA ... bring about a price reduction ranging between 2.14% to ... hearing to explain the reasons for steep price increase ...
... Gengraine Technologies (Avesthagen) of India is collaborating// with ... Developing Countries (IFU) of Germany for Osteoporosis research. ... euro. Avesthagen said “"The alliance will cover diagnosis, ... disorders.” The research studies related to menopause linked ...
... patients with diastolic heart failure increases// the survival rate ... ,William C. Little and his research team from ... heart failure (DHF) treated with statins has better survival ... failure patients published in the Journal Circulation: Journal of ...
... For the elderly population, adjusting to the raising temperatures// in ... heat that may affect the elderly people are heat exhaustion ... Health Letter from the Harvard Medical School had given some ... a little easier during the summers. ,In addition to ...
... article reviewing the research carried out so far into the ... revealed that a new phase III trial is scheduled to ... CoQ10 has escalated, causing soaring prices and reports of fake ... to have been triggered by the publication of Shults’ earlier ...
Cached Medicine News:Health News:Hypertension can be caused by Inhalation of Salt 2Health News:Hypertension can be caused by Inhalation of Salt 3Health News:Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients 2Health News:Elderly People Needs To Tackle The Heat Effectively 2Health News:New Study to look at the Beneficial Effects of Coenzyme Q10 on Parkinson’s disease 2
Toxoplasma IgM II ELISA....
Herpes Simplex Virus 2 IgG ELISA....
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of small sized foreign bodies....
Blunt tipped forceps with long thin tips (3 mm) angled at approximately 120. For grasping of subretinal membranes. Color Coding: Gold....
Medicine Products: